Document is current
Any future updates will be listed below
-
Authors
Zhao, Maryann https://orcid.org/0000-0001-9325-4066
Schoenfeld, Jonathan D. https://orcid.org/0000-0002-5119-0401
Egloff, Ann Marie
Hanna, Glenn J.
Haddad, Robert I.
Adkins, Douglas R.
Uppaluri, Ravindra https://orcid.org/0000-0001-5988-6828
- License Information
-
More Information
Article History
Accepted: 8 November 2024
First Online: 10 December 2024
Competing interests
: G.J.H. has acted as a consultant and/or adviser of and/or received research funding from Bicara, BMS, Exicure, Gateway for Cancer Research, GSK, Kite Pharma, Maverick, Merck, NantKwest/Altor Bioscience, Regeneron, Sanofi Genzyme and Secura Bio. J.D.S. has received research funding from BMS, Debiopharm, Merck and Regeneron, and has acted as a consultant and/or adviser of ACI Clinical, Astellas, Castle Biosciences, Catenion, Debiopharn, Genentech, Immunitas, LEK and Merck KGA, and owns equity in Doximity and Immunitas. R.I.H. has acted as a consultant and/or adviser for, and had received research funding from, AstraZeneca, Bayer, BMS, Eisai, GSK, ISA, Kura, Merck, Mirati, Nanobiotix, NCCN and Pfizer. D.R.A. has acted as a consultant and/or adviser for Celgene, Cue Biopharma, Eli Lilly, Loxo Oncology, Merck and Pfizer, and has received research funding from Aduro, Astrazeneca, Atara, Blueprint Medicine, Celgene, Celldex, Cue Biopharma, Eli Lilly, Enzychem, Exilixis, Innate, Kura, Matrix, Medimmune, Novartis, Pfizer, Roche and Shanghai De Novo. R.U. has acted as a consultant and/or adviser for Daiichi–Sankyo, Merck and Regeneron, and has received research funding from Merck. The remaining authors declare no competing interests.
